Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Journal
The Lancet. Oncology
Journal Volume
23
Journal Issue
1
Pages
77
Date Issued
2022-01
Author(s)
Yau, Thomas
Park, Joong-Won
Finn, Richard S
Mathurin, Philippe
Edeline, Julien
Kudo, Masatoshi
Harding, James J
Merle, Philippe
Rosmorduc, Olivier
Wyrwicz, Lucjan
Schott, Eckart
Choo, Su Pin
Kelley, Robin Kate
Sieghart, Wolfgang
Assenat, Eric
Zaucha, Renata
Furuse, Junji
Abou-Alfa, Ghassan K
El-Khoueiry, Anthony B
Melero, Ignacio
Begic, Damir
Chen, Gong
Neely, Jaclyn
Wisniewski, Tami
Tschaika, Marina
Sangro, Bruno
Abstract
Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma.
Subjects
THERAPY
Publisher
ELSEVIER SCIENCE INC
Type
journal article